Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda variable (VI)-22-1 encodes a variable region of the lambda light chain of immunoglobulins (antibodies)[5][3]. This domain contributes to antigen recognition and binding, forming part of the antigen-specific binding site together with the variable region of the heavy chain[2][3]. The lambda light chain is encoded at chromosome 22q11.2 and comprises multiple variable region genes with distinct subgroups[5][1]. Antibodies are composed of two heavy and two light chains (in humans, either kappa or lambda type), and each B cell expresses only one light chain class[3][1]. The immunoglobulin variable regions are generated by somatic recombination and hypermutation, ensuring immune diversity and specificity[1][3]. Lambda light chains, including the variable region encoded by IGLV(VI)-22-1, are important in both normal immune function and in disease contexts such as lymphoid malignancies and plasma cell dyscrasia, where changes in their expression are clinically relevant[3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda variable (VI)-22-1 (IGLV(VI)-22-1).